Home
About CBI
Now more than ever before, the power to turn huge volumes of data into information about our world has put the answers to some of life’s most challenging questions within our grasp. The George Washington University’s Computational Biology Institute (CBI) brings together leading faculty in biology, medicine and computing to harness this information, opening new doors of discovery that have the potential to benefit millions. CBI is also maximizing the university’s unique relationships in the nation’s capital to form research partnerships and spotlight cutting-‐edge topics that enhance human and environmental health. By blending its own skills with the expertise of engineers, mathematicians, statisticians, clinicians and others, the CBI is contributing to knowledge and resources that are used by researchers on a global scale, influencing how the world uses science and technology to solve its most pressing problems. With these truly incomparable resources and expertise, the CBI performs cutting-edge research and helps raise awareness of scientific advancements that improve our health, environment and overall quality of life.
RANKED #11
U.S. News & World Report's List of Best Public Health Graduate Programs
LOCATION
Washington D.C.'s only Public Health School
RESEARCH
Shaping Public Health Policy and Practice
FACULTY
130 Full-time Faculty Leading our Students, and 300 Part-time Faculty.
Featured Publications
Estimating rare disease prevalence and costs in the USA: a cohort study approach using the Healthcare Cost Institute claims data
December 20, 2024
Estimating rare disease prevalence and costs in the USA: a cohort study approach using the Healthcare Cost Institute claims data
High-sensitivity pattern discovery in large, paired multiomic datasets
December 20, 2024
We present a novel framework which integrates hierarchical hypothesis testing with FDR correction to reveal linear and non-linear relationships among data.
Association of Early Aspirin Use With In-Hospital Mortality in Patients With Moderate COVID-19
December 20, 2024
Prior studies suggest aspirin may be associated with reduced mortality in high-risk patients with COVID-19, but patients with moderate COVID-19 are not studied.
546 Therapeutic beta-lactam dosages and broad-spectrum antibiotics are associated with short-term reductions in microbial richness and beta-diversity
December 20, 2024
People with cystic fibrosis have morbid pulmonary exacerbations. Antibiotics are common, yet the beta-lactam doses administered are less than half the time.
